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Abstract 
Live plague vaccines have saved thousands of human lives in the 20th century and have continued to be 
used in Russia and other countries of the former Soviet Union for prophylaxis of plague. A live attenuated 
Y. pestis EV strain line NIIEG is used for the routine annual vaccination of plague workers, as well as 
people from the groups at risk. This vaccination can offer immunity against both bubonic and pneumonic 
plague. However, serologic markers of the human response to vaccination with EV NIIEG are poorly 
investigated. It is not clear whether other antigens, in addition to the established capsular antigen F1 and 
lipopolysaccharide, can elicit specific and long-lasting antibody responses in vaccinees. In this study, a 
humoral immunity to a panel of recombinant Y. pestis-specific antigens, such as F1, Pla, LcrV, YopM and 
YscF, was examined in volunteers, who received multiple annual immunizations with EV NIIEG during 
the period of 5 to 30 years. To evaluate a long-term immune response to these antigens, we chose a cohort 
of donors, who had their last immunization 4-30 years ago. The immunoblotting technique revealed that 
sera of 14 out of 17 donors contained antibodies to at least one of the tested antigens. As expected, the 
occurrence of anti-F1 antibodies was detected in a large group of vaccinees (57%). In contrast, the 
presence of specific antibodies to either LcrV or YscF was less pronounced (26% and 36%, respectively), 
and only two donors possessed anti-YopM (10%). Surprisingly, we found that sera of the vast majority of 
volunteers (82%) gave positive reaction with the outer membrane protease Pla, specific to Y. pestis. This 
analysis will provide insights into the correlates of immunity elicited in humans by live plague vaccine, 
aid in the search for markers of exposure to plague, and help to develop new diagnostic protocols. 
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1. Main text  
Vaccination with live attenuated Y. pestis EV76 and its derivatives can elicit in humans both cellular 
and humoral immunity efficient against all forms of plague [1-3]. This protective immunity is directly 
correlated with the ability of the vaccine strain to survive, persist, multiply and disseminate in the regional 
lymph nodes and tissues for a limited time. The anti-F1-antibody response was routinely used to evaluate 
the efficacy of the EV76, the EV NIIEG vaccine in humans and several animal species inoculated by 
different routes. The analysis of sera of humans vaccinated cutaneously with EV NIIEG for the period 
from 1 to 30 years revealed the overall presence of antibodies to F1 antigen in approximately half of 
vaccinees [4]. Nevertheless, vaccinated individuals who did not possess F1-specific serum antibodies still 
may provide a strong T-cell recall to F1 antigen [5]. 
The aim of our study was to investigate a humoral immunity in vaccinees, who received multiple 
annual immunizations with EV NIIEG to a panel of recombinant Y. pestis-specific antigens, such as F1, 
Pla, LcrV, YopM and YscF. 
1.1. Methods 
Antibody response was examined in humans, who received multiple annual immunizations with the 
live plague vaccine EV NIIEG during the period of 5 to 30 years. To evaluate a long-term immune 
response to these antigens, we chose a cohort of donors, who had their last immunization 4-30 years ago. 
The presence of the antigen-specific antibodies in sera of the donors was detected by immunoblotting 
technique. A panel of recombinant Y. pestis antigens, such as F1, Pla, LcrV, YopM and YscF, was 
obtained after cloning and expression of these proteins in E. coli in a form of fusion peptides with His-
Tag, followed by their purification by Ni2+- chromatography [5]. 
1.2. Results 
Antibodies to at least one of the tested antigens, i.e. Y. pestis F1, LcrV, YopM, YscF and Pla were 
detected in sera of 14 of 17 vaccinees (82%). Importantly, sera of the vast majority of volunteers (82%) 




















Fig. 1. Comparative diagnostic value of the recombinant Y. pestis antigens, such as F1, LcrV, YopM, YscF and Pla 
based on a percentage of vaccinees with the positive antibody response to each of the antigens tested in immunoblot. 
 
12   V.A. Feodorova et al. /  Procedia in Vaccinology  6 ( 2012 )  10 – 13 
Serum obtained from a single donor uniquely contained antibodies to all five Y. pestis antigens (Fig. 2). 
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Fig. 2. Immunoblot to determine the antigenic specificity of immune antiserum obtained from one of the vaccines. 
The recombinant antigens F1, Pla, LcrV, YopM and YscF contain His-Tag. The F1-Y.p is a capsular subunit purified 
directly from Y. pestis.  
 
Sera from 3 out of 17 donors (17%) did not possess antibodies to any antigens tested in this study. 
Sera obtained from the vast majority of donors contained antibodies to either Pla antigen alone (Fig. 3A) 
or Pla in combination with other Y. pestis antigen(s) (Fig. 3B). 
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Fig. 3. Representative immunoblot illustrating the unique reaction of donor’s antisera with either the Pla antigen 
alone (A) or Pla and additional antigen (LcrV) (B). 
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1.3. Conclusions 
1. The use of a panel of recombinant protein antigens of Y. pestis showed that multiple human 
vaccinations with the live EV NIIEG can result in eliciting a robust antibody response to a different 
combination of the antigens.  
2. The outer membrane protease Pla is considered to be an excellent marker for evaluation of a 
long-term immunity to plague in humans in addition to the capsular antigen F1.  
3. We showed for the first time that a large percent of sera (36% in this study) from the vaccines 
contained antibodies to a small protein YscF, a major subunit component of the translocation needle for 
the type 3 secretion system. 
4. A search for additional markers of exposure to plague should be continued by using a whole 
proteome approach.  
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